CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.

CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).

Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

Eli Lilly saw significant growth driven by Mounjaro and Zepbound, with Q3 2024 revenues reaching $3.11 billion and $1.26 billion, respectively.

Novo Nordisk expanded its GLP-1 market presence, tripling the number of patients using its treatments to 11.5 million. The company reported strong growth in diabetes care, with a 21% revenue increase, outpacing the market.

Eli Lilly vs Novo Nordisk In the one last year, Merck’s stock price has delivered a negative return of 17%, while Pfizer stock delivered a positive return of 3.91% in the same period.

Novo Nordisk expanded its GLP-1 market presence, tripling the number of patients using its treatments to 11.5 million. The company reported strong growth in diabetes care, with a 21% revenue increase, outpacing the market.